METHODS FOR DETERMINING THE MECHANISM OF TARGETED PROTEIN DEGRADATION

Abstract

Summary. Targeted protein degradation (TPD) is a modern strategy for developing new therapeutic agents that requires not only detection of decreased target abundance but also stepwise validation of the compound’s mechanism of action. In this approach, the disappearance of the target protein is necessary but insufficient, because it does not by itself distinguish proteasomal degradation from inhibition of protein synthesis, loss of antibody epitope, toxicity, or altered protein solubility. Therefore, degrader analysis should rely on a hierarchy of methods that sequentially assess target protein abundance, selectivity and kinetics, compound binding to the target or E3 ligase, ternary complex formation, ubiquitination, and dependence of target loss on proteasomal clearance. This article summarizes methods used in degrader development and groups them by the measured parameter, type of experimental response, and mechanistic information provided by each method. Objective: to define a hierarchy of methods used to study protein degraders and to show which stage of the mechanism of action is assessed by each group of methods. Conclusions. Rational development of protein degraders cannot rely solely on the observed decrease in target protein abundance. Quantitative, biophysical, cellular, structural, and causal assays should be combined to confirm compound binding, formation of a productive E3-ligase complex, target ubiquitination, and proteasomedependent degradation. This stepwise evidentiary framework reduces the risk of false interpretation and supports more rational optimization of molecules. Keywords: targeted protein degradation, ternary complex, luminescence, fluorescence.